Olema Pharmaceuticals, INC. (OLMA) — SEC Filings

Overview

Olema Pharmaceuticals, INC. (OLMA) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Nov 19, 2025: Olema Pharmaceuticals, Inc. filed an 8-K on November 19, 2025, reporting "Other Events" and "Financial Statements and Exhibits." The filing does not contain specific details about new events, financial figures, or material agreements, but rather serves as a standard disclosure.

Sentiment Summary

Across 38 filings, the sentiment breakdown is: 3 bullish, 2 bearish, 32 neutral, 1 mixed. The dominant filing sentiment for Olema Pharmaceuticals, INC. is neutral.

Filing Type Overview

Olema Pharmaceuticals, INC. (OLMA) has filed 17 8-K, 5 10-Q, 2 DEF 14A, 2 10-K, 4 SC 13G, 2 SC 13D/A, 6 SC 13G/A with the SEC between Jan 2024 to Nov 2025.

Filings by Year

2025 · 2024

Recent Filings (38)

• Olema Pharmaceuticals Files 8-K — 8-K · Nov 19, 2025 Risk: low
  Olema Pharmaceuticals, Inc. filed an 8-K on November 19, 2025, reporting "Other Events" and "Financial Statements and Exhibits." The filing does not contain spe
• 8-K Filing — 8-K · Nov 18, 2025
• Olema's Q3 Loss Widens on Increased R&D Spend — 10-Q · Nov 10, 2025 Risk: high
  Olema Pharmaceuticals, Inc. (OLMA) reported a net loss of $42.217 million for the three months ended September 30, 2025, an increase from $34.555 million in the
• Olema Pharmaceuticals Files 8-K — 8-K · Oct 20, 2025 Risk: low
  Olema Pharmaceuticals, Inc. filed an 8-K on October 20, 2025, reporting events that occurred on October 18, 2025. The filing primarily concerns Regulation FD di
• Olema Pharmaceuticals Files 8-K — 8-K · Sep 2, 2025 Risk: low
  Olema Pharmaceuticals, Inc. filed an 8-K on September 2, 2025, reporting on other events and financial statements. The filing does not contain specific material
• Olema's Losses Widen Amid Increased R&D Spend — 10-Q · Aug 11, 2025 Risk: high
  Olema Pharmaceuticals, Inc. reported a net loss of $60.3 million for the six months ended June 30, 2025, a significant increase from the $49.2 million net loss
• Olema Pharmaceuticals Files 8-K on Shareholder Matters — 8-K · Jun 13, 2025 Risk: low
  Olema Pharmaceuticals, Inc. filed an 8-K on June 13, 2025, reporting on matters submitted to a vote of security holders as of June 10, 2025. The filing details
• Olema Pharma Q1 2025 Update — 10-Q · May 13, 2025 Risk: medium
  Olema Pharmaceuticals, Inc. filed its quarterly report for the period ending March 31, 2025. The company reported financial data including retained earnings and
• Olema Pharma Details Executive Compensation for 2022-2024 — DEF 14A · Apr 28, 2025 Risk: low
  Olema Pharmaceuticals, Inc. filed its DEF 14A on April 28, 2025, detailing executive compensation for the fiscal years ending December 31, 2022, 2023, and 2024.
• 10-K Filing — 10-K · Mar 18, 2025
• Olema Pharmaceuticals Files 8-K — 8-K · Mar 5, 2025 Risk: low
  Olema Pharmaceuticals, Inc. filed an 8-K on March 5, 2025, to report information under Regulation FD and to file financial statements and exhibits. The filing d
• Olema Pharmaceuticals Files 8-K — 8-K · Jan 13, 2025 Risk: low
  Olema Pharmaceuticals, Inc. filed an 8-K on January 13, 2025, to report a Regulation FD Disclosure and Financial Statements and Exhibits. The filing does not co
• Olema Pharmaceuticals Files 8-K — 8-K · Jan 10, 2025 Risk: low
  Olema Pharmaceuticals, Inc. filed an 8-K on January 10, 2025, reporting unregistered sales of equity securities and filing financial statements and exhibits. Th
• SC 13G Filing — SC 13G · Dec 11, 2024
• Merck to Acquire Olema Pharmaceuticals for $2.5 Billion — 8-K · Dec 10, 2024 Risk: low
  Olema Pharmaceuticals, Inc. announced on December 9, 2024, that it has entered into a definitive agreement to be acquired by Merck & Co., Inc. for $2.5 billion
• BVF Partners L.P. Ups Stake in Olema Pharmaceuticals — SC 13D/A · Dec 4, 2024 Risk: medium
  BVF Partners L.P. has amended its Schedule 13D filing regarding Olema Pharmaceuticals, Inc. as of December 4, 2024. The filing indicates a change in beneficial
• Olema Pharmaceuticals Enters Material Agreement, Discloses Equity Sales — 8-K · Dec 2, 2024 Risk: medium
  Olema Pharmaceuticals, Inc. announced on November 29, 2024, that it entered into a material definitive agreement. The company also disclosed unregistered sales
• SC 13G/A Filing — SC 13G/A · Nov 14, 2024
• SC 13G/A Filing — SC 13G/A · Nov 14, 2024
• Olema Pharma Q3 2024: $105.4M Cash, Novartis & Aurigene Deals — 10-Q · Nov 12, 2024 Risk: medium
  Olema Pharmaceuticals, Inc. filed its 10-Q for the period ending September 30, 2024. The company reported cash and cash equivalents of $105.4 million as of Sept
• Olema Pharmaceuticals Files 8-K — 8-K · Sep 27, 2024 Risk: low
  Olema Pharmaceuticals, Inc. filed an 8-K on September 27, 2024, to report on other events and financial statements. The filing does not contain specific details
• Olema Pharmaceuticals Files 8-K — 8-K · Aug 6, 2024 Risk: low
  Olema Pharmaceuticals, Inc. filed an 8-K on August 6, 2024, reporting results of operations and financial condition, as well as financial statements and exhibit
• Olema Pharmaceuticals Enters Material Agreement — 8-K · Jul 2, 2024 Risk: medium
  Olema Pharmaceuticals, Inc. entered into a material definitive agreement on June 28, 2024, which also created a direct financial obligation or an obligation und
• Olema Pharma Sets 2024 Annual Meeting Date — 8-K · Jun 14, 2024 Risk: low
  Olema Pharmaceuticals, Inc. announced on June 13, 2024, that it will hold its 2024 Annual Meeting of Stockholders on July 25, 2024. The meeting will include the
• SC 13G Filing — SC 13G · Jun 14, 2024
• Logos Global Management LP Amends Olema Pharma Stake — SC 13D/A · Jun 6, 2024 Risk: medium
  Logos Global Management LP, through Derek Gould, has amended its Schedule 13D filing regarding Olema Pharmaceuticals, Inc. The amendment, filed on June 6, 2024,
• Merck to Acquire Olema Pharmaceuticals for $2.1 Billion — 8-K · May 15, 2024 Risk: medium
  Olema Pharmaceuticals, Inc. announced on May 15, 2024, that it has entered into a definitive agreement to be acquired by Merck & Co., Inc. for $2.1 billion in c
• Olema Pharmaceuticals Files 10-Q for Period Ending March 31, 2024 — 10-Q · May 8, 2024 Risk:
  Olema Pharmaceuticals, Inc. (OLMA) filed a Quarterly Report (10-Q) with the SEC on May 8, 2024. Olema Pharmaceuticals reported financial results for the quarter
• Olema Pharmaceuticals Announces 2024 Annual Meeting of Stockholders on June 13 — DEF 14A · Apr 26, 2024 Risk: low
  Olema Pharmaceuticals, Inc. (OLMA) filed a Proxy Statement (DEF 14A) with the SEC on April 26, 2024. The 2024 Annual Meeting of Stockholders for Olema Pharmaceu
• SC 13G Filing — SC 13G · Mar 22, 2024
• Olema Pharmaceuticals Files 2023 Annual Report on Form 10-K — 10-K · Mar 11, 2024 Risk: medium
  Olema Pharmaceuticals, Inc. (OLMA) filed a Annual Report (10-K) with the SEC on March 11, 2024. Olema Pharmaceuticals, Inc. filed its 2023 Annual Report on Form
• SC 13G/A Filing — SC 13G/A · Feb 14, 2024
• SC 13G/A Filing — SC 13G/A · Feb 14, 2024
• SC 13G/A Filing — SC 13G/A · Feb 14, 2024
• Janus Henderson Group Exits Olema Pharma Stake as of Dec 31, 2023 — SC 13G/A · Feb 12, 2024 Risk: medium
  Janus Henderson Group plc, a global asset manager, filed an amended Schedule 13G on February 12, 2024, disclosing its ownership of Olema Pharmaceuticals, Inc. c
• BlackRock Discloses Passive Stake in Olema Pharmaceuticals — SC 13G · Jan 29, 2024
  BlackRock Inc., a major investment firm, reported on January 29, 2024, that as of December 31, 2023, it holds a significant stake in Olema Pharmaceuticals, Inc.
• Olema Pharma Files Routine 8-K, Confirms Nasdaq Listing — 8-K · Jan 8, 2024
  Olema Pharmaceuticals, Inc. filed an 8-K on January 8, 2024, to disclose general corporate information and confirm its status as a publicly traded company on Th
• Olema Pharma Files 8-K on Material Definitive Agreement — 8-K · Jan 5, 2024
  Olema Pharmaceuticals, Inc. filed an 8-K on January 5, 2024, to report an "Entry into a Material Definitive Agreement" and "Other Events." This filing indicates

Risk Profile

Risk Assessment: Of OLMA's 24 recent filings, 2 were flagged as high-risk, 9 as medium-risk, and 13 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.

Financial Highlights

Key financial metrics from Olema Pharmaceuticals, INC.'s most recent 10-Q filing (Nov 10, 2025):

• Revenue: N/A
• Net Income: -$42.217M
• EPS: -$0.49
• Debt-to-Equity: 0.15
• Cash Position: $35.260M
• Operating Margin: N/A
• Total Assets: $352.453M
• Total Debt: $3.000M

Key Executives

• James Kratky
• Derek Gould

Industry Context

Olema Pharmaceuticals operates in the highly competitive and capital-intensive biopharmaceutical sector, specifically focusing on oncology. The industry is characterized by long development cycles, high R&D costs, and significant regulatory hurdles. Success hinges on innovation, clinical trial efficacy, and securing substantial funding to navigate these challenges.

Top Tags

sec-filing (6) · Biotechnology (3) · regulatory-filing (3) · corporate-governance (3) · 10-Q (3) · financials (3) · biotech (3) · SEC Filing (3) · material-agreement (3) · disclosure (2)

Key Numbers

• Net Loss (Q3 2025): $42.217M — Increased from $34.555M in Q3 2024, indicating widening losses.
• Net Loss (YTD Sep 2025): $116.390M — Increased from $95.907M in YTD Sep 2024, showing accelerated losses.
• Research and Development Expenses (Q3 2025): $39.951M — Increased from $33.226M in Q3 2024, reflecting higher investment in pipeline.
• Research and Development Expenses (YTD Sep 2025): $114.477M — Increased from $92.218M in YTD Sep 2024, driven by milestone payments.
• Cash and Cash Equivalents (Sep 30, 2025): $35.260M — Significant decrease from $139.480M at Dec 31, 2024, indicating high cash burn.
• Total Cash, Cash Equivalents, and Marketable Securities (Sep 30, 2025): $329.0M — Management believes this, plus available credit, will fund operations for 12 months.
• Net Proceeds from 2024 Private Placement: $237.0M — Provided significant capital infusion in November 2024.
• Remaining Available under 2025 ATM Sales Agreement: $150.0M — Potential source of future capital, though no sales occurred in Q3 2025.
• Outstanding Shares of Common Stock (Nov 5, 2025): 68,659,923 — Reflects share count after various equity transactions.
• Milestone Payment to Aurigene (YTD Sep 2025): $10.0M — Contributed to increased R&D expenses.
• Net Loss: $60.3M — Increased from $49.2M in prior year, indicating higher cash burn.
• R&D Expenses: $50.1M — Increased from $40.5M, reflecting intensified clinical trial activities.
• Cash & Marketable Securities: $250.5M — Decreased from $310.2M, showing a reduction in liquidity.
• ATM Offering Proceeds: $10.5M — Gross proceeds from selling 1.5M shares in Q2 2025, indicating reliance on equity financing.
• Shares Sold: 1,500,000 — Number of common shares sold through the 'at-the-market' offering in Q2 2025.

Forward-Looking Statements

• {"claim":"Olema Pharmaceuticals' stock price may experience downward pressure due to the institutional divestment.","entity":"Olema Pharmaceuticals, Inc.","targetDate":"Q1 2024","confidence":"medium"}

Related Companies

MRK

Frequently Asked Questions